72.17
+0.04(+0.06%)
Currency In USD
Address
10578 Science Center Drive
San Diego, CA 92121
United States of America
Phone
858 401 7900
Sector
Healthcare
Industry
Biotechnology
Employees
391
First IPO Date
June 12, 2020
| Name | Title | Pay | Year Born |
| Sarah Boyce | President, Chief Executive Officer & Director | 1.27M | 1972 |
| Eric Mosbrooker | Chief Commercial Officer | 45,000 | 1967 |
| Troy Edward Wilson | Co-Founder & Independent Chairman | 71,908 | 1969 |
| John Moriarty Jr. ESQ. | Chief Legal Officer & Corporate Secretary | 683,588 | 1968 |
| Teresa McCarthy | Chief Human Resources Officer | 782,410 | 1964 |
| Michael F. MacLean | Chief Financial Officer | 839,110 | 1966 |
| W. Michael Flanagan | Chief Scientific Officer | 855,110 | 1962 |
| Steven George Hughes | Chief Medical Officer | 0 | 1967 |
| Charles Calderaro | Chief Technical Officer | 0 | 1964 |
| Kathleen Gallagher | Chief Program Officer | 0 | 1981 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.